These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1703239)

  • 1. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience.
    Matzkin H; Chen J; Lewysohn O; Braf Z
    J Urol; 1991 Feb; 145(2):309-12. PubMed ID: 1703239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy.
    Gabrilove JL; Levine AC; Kirschenbaum A; Droller M
    J Clin Endocrinol Metab; 1989 Sep; 69(3):629-32. PubMed ID: 2474565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide.
    Levine AC; Kirschenbaum A; Kaplan P; Droller MA; Gabrilove JL
    Urology; 1989 Jul; 34(1):10-3. PubMed ID: 2473567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
    Peters CA; Walsh PC
    N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy.
    Gabrilove JL; Levine AC; Kirschenbaum A; Droller M
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1331-3. PubMed ID: 2437142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy.
    Levine AC; Kirschenbaum A; Droller M; Gabrilove JL
    J Urol; 1991 Sep; 146(3):790-3. PubMed ID: 1714969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of LH-RH analogue in benign prostatic hyperplasia].
    Ferretti S; Salsi P; Arena F; Peracchia G; Cortellini P
    Acta Biomed Ateneo Parmense; 1993; 64(1-2):23-7. PubMed ID: 7518631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist.
    Schlegel PN; Brendler CB
    Urology; 1989 Aug; 34(2):69-72. PubMed ID: 2474882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum bioactive and immunoreactive follicle stimulating hormone during chronic treatment with gonadotropin releasing hormone agonist in elderly men.
    Matzkin H; Braf Z; Dekel N
    Horm Metab Res; 1991 Feb; 23(2):76-80. PubMed ID: 1710593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of acute urine retention caused by benign prostatic hypertrophy with an LH-RH agonist (Goserelin)].
    Puyol Pallas M; Gómez Parada J
    Actas Urol Esp; 1995 Feb; 19(2):118-22. PubMed ID: 7539571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of complicated benign prostatic hyperplasia with LHRH-analogues in aged patients.
    Bianchi S; Gravina G; Podestà A; Barletta D; Franchi F; Kicovic P; Luisi M
    Int J Androl; 1989 Apr; 12(2):104-9. PubMed ID: 2470690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of LH-RH analogue in patients with benign prostatic hyperplasia.
    Lukkarinen O
    Urology; 1991 Feb; 37(2):92-4. PubMed ID: 1704161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [LH-RH agonists as therapeutic alternative in patients with benign prostatic hyperplasia (BPH) and surgical contraindication. Long term follow up].
    Granados Loarca EA; Chéchile Toniolo G; Villavicencio Mavrich H
    Arch Esp Urol; 1996 Nov; 49(9):923-7. PubMed ID: 9133292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [GnRH antagonists and benign prostatic hyperplasia].
    Comaru-Schally dM
    Ann Urol (Paris); 2005 Oct; 39 Suppl 3():S73-7. PubMed ID: 16302715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.